These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31705590)

  • 1. Recalcitrant trametinib-induced paronychia treated successfully with topical timolol in a pediatric patient.
    Martínez-de-Espronceda I; Bernabeu-Wittel J; Azcona M; Monserrat MT
    Dermatol Ther; 2020 Jan; 33(1):e13164. PubMed ID: 31705590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma.
    Ronsley R; Hounjet CD; Cheng S; Rassekh SR; Duncan WJ; Dunham C; Gardiner J; Ghag A; Ludemann JP; Wensley D; Rehmus W; Sargent MA; Hukin J
    Cancer Med; 2021 Jun; 10(11):3556-3564. PubMed ID: 33939292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are topical beta-blockers really effective "in real life" for targeted therapy-induced paronychia.
    Sibaud V; Casassa E; D'Andrea M
    Support Care Cancer; 2019 Jul; 27(7):2341-2343. PubMed ID: 30847700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies.
    Olamiju B; Bhullar S; Coleman EL; Leventhal JS
    J Am Acad Dermatol; 2021 Mar; 84(3):806-808. PubMed ID: 32526318
    [No Abstract]   [Full Text] [Related]  

  • 5. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
    Cox DS; Allred A; Zhou Y; Infante JR; Gordon MS; Bendell J; Jones S; Burris H; Orford K
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):287-94. PubMed ID: 27136909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine.
    Cubiró X; Planas-Ciudad S; Garcia-Muret MP; Puig L
    JAMA Dermatol; 2018 Jan; 154(1):99-100. PubMed ID: 29117285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor.
    Lazow MA; Lawson SA; Salloum R; Hummel TR; Pillay Smiley N; DeWire-Schottmiller MD; Fouladi M; de Blank P
    J Pediatr Hematol Oncol; 2021 May; 43(4):e550-e553. PubMed ID: 32520842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
    Patnaik A; Tolcher A; Papadopoulos KP; Beeram M; Rasco D; Werner TL; Bauman JW; Scheuber A; Cox DS; Patel BR; Zhou Y; Hamid M; Schramek D; Sharma S
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):491-500. PubMed ID: 27392790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study.
    Yen CF; Hsu CK; Yang HS; Lee CN; Chi CC; Chung WH; Wang CL; Pang JS; Wang CW; Ko YS; Lu CW
    Int J Dermatol; 2020 Mar; 59(3):326-332. PubMed ID: 31763692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychological impact of trametinib in pediatric low-grade glioma: A case series.
    Peterson RK; McKeown T; Tabori U; Bartels U; Bouffet E; Janzen L
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28690. PubMed ID: 32930446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trametinib-Associated Bradycardia.
    Alhazmi L; Karim MM; Al-Sarie M; Skeel R; Karim S
    Am J Ther; 2019; 26(5):e657-e659. PubMed ID: 31241492
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan.
    Liu HL; Chuang CH; Chen CL; Wei PJ; Yang CJ
    J Oncol Pharm Pract; 2023 Sep; 29(6):1374-1380. PubMed ID: 36112905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
    Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
    Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumocephalus in a Pediatric Patient with Glioma Receiving Trametinib.
    Gorsi H; Marupudi NI; Sood S; Altinok D; Yankelevich M
    Pediatr Neurosurg; 2020; 55(1):51-53. PubMed ID: 31661699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors.
    Boull C; Hook K; Moertel C; Maguiness S
    Pediatr Dermatol; 2017 Jan; 34(1):90-94. PubMed ID: 27981612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous Reactions in Pediatric Patients Treated with MEK Inhibitors: A Retrospective Single-Center Study.
    Friedland R; Glick M; Amitay-Laish I; Toledano H
    Dermatology; 2024; 240(4):565-571. PubMed ID: 38772345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
    Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of pediatric pyogenic granulomas using β-adrenergic receptor antagonists.
    Wine Lee L; Goff KL; Lam JM; Low DW; Yan AC; Castelo-Soccio L
    Pediatr Dermatol; 2014; 31(2):203-7. PubMed ID: 24138457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.